News
Cytoreductive nephrectomy may benefit RCC patients with brain mets
In an analysis of SEER data, 2-year survival was 52% and 14%, respectively, for RCC patients with brain-only metastases who did and did not...
News
Lipoprotein ratio linked to poor survival in metastatic RCC
In a retrospective study of data on 287 metastatic RCC patients who underwent cytoreductive nephrectomy, the ratio of apolipoproteins B and A1 was...
News
RCC strongly linked to melanoma, and vice versa
Clinicians need to be vigilant for RCCs in melanoma patients, and for melanomas in RCC patients.
News
Emapalumab found safe, effective in primary HLH
SAN DIEGO—Emapalumab, an interferon gamma-blocking antibody, controls disease activity and has a favorable safety profile in pediatric patients...
News
Rapid test could solve Africa’s sickle cell screening problem
SAN DIEGO – The simple blood test costs about $2 and has an accuracy of 99%.
Video
Rivaroxaban may reduce VTE risk in cancer patients
SAN DIEGO – The CASSINI trial evaluates VTE prophylaxis in ambulatory patients receiving systemic therapy.
News
HU could save millions of lives in Africa, speaker says
SAN DIEGO—Daily hydroxyurea (HU) treatment is feasible, safe, and effective for children with sickle cell disease (SCD) in sub-Saharan Africa,...
Video
DOAC pause yields favorable outcomes for AF patients
SAN DIEGO – Results from the PAUSE study could set the standard for timing of perioperative DOAC interruption.
News
Early intervention initiative cut oncology patient hospitalizations
An after-hours phone triage system, proactive chemotherapy follow-up calls, and a Saturday-Sunday urgent care clinic resulted in early...
Video
Sickle cell disease guidelines release set for early 2019
SAN DIEGO – Five new ASH guidelines for sickle cell disease are on the way, likely early in 2019.
News
Emapalumab safe, effective in pediatric primary hemophagocytic lymphohistiocytosis
SAN DIEGO – There is “certainly room for enlarging the indication” to first-line treatment of HLH once a sufficient number of previously untreated...
News
Ixazomib improves PFS after ASCT in MM
SAN DIEGO—Ixazomib improved progression-free survival (PFS) following autologous stem cell transplant (ASCT) in patients with newly diagnosed...
News
Lower-dose rituximab may be enough in acquired TTP
SAN DIEGO – A lower dose of rituximab appears effective, but it still carries side effects.
News
Luspatercept reduced transfusion burden in MDS patients
SAN DIEGO—Results of the randomized, phase 3 Medalist trial show that the erythroid maturation agent luspatercept can reduce transfusion burden in...
News
TOURMALINE-MM3: Ixazomib improves PFS after myeloma transplant
SAN DIEGO – A leading investigator put the results in perspective with the currently approved lenalidomide, and the audience questions as to...